Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Acadia Pharmaceuticals (ACAD) stock in plain English

Free brief · no signupStart here
ACADPublished Nov 18, 2026
Acadia Pharmaceuticals Inc
Healthcare · Biotechnology
Sells prescription drugs that treat Parkinson's disease psychosis and Rett syndrome in the United States.
Assets:
Two commercial medicinesNuplazid for Parkinson's psychosis and Daybue for Rett syndrome
San Diego headquartersPrimary corporate offices and clinical management operations based in California
Specialized commercial staffDedicated field sales teams and medical affairs liaisons covering neurology specialists
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

82
OPS ScoreOperating finances
Latest quote
-1.35%$17.59
$3.04B
8.4×
$1.20B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was ACAD. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Acadia Pharmaceuticals (ACAD) do?

Acadia Pharmaceuticals Inc (ACAD) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells prescription drugs that treat Parkinson's disease psychosis and Rett syndrome in the United States. Develops and commercializes targeted central nervous system therapies for rare neurological conditions and Parkinson's. It is worth $3.04B on the market and sold $1.20B over the last year.

Market cap
$3.04B
P/E ratio
8.4×
Annual sales
$1.20B
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 18, 2026

Brands and businesses behind ACAD

  • Nuplazid: Prescription medicine sold to treat hallucinations and delusions associated with Parkinson's disease psychosis.
  • Daybue: Prescription oral solution sold to treat Rett syndrome in adult and pediatric patients.

ACAD’s flags, in plain English

Each flag is a number from Acadia Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Low debt

Low debt, only 5% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 90.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Stupid Cash

Can pay this year's bills 3.8 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Profit with Caveats

Bottom-line profit of $362M in the 12 months to Sep 30, 2026, next to $122M of profit from the business. Bottom-line profit is well above what the business itself earned. The difference came from outside day-to-day operations, such as an investment gain, a tax benefit, the sale of a business or interest on its cash. Some of these may not repeat, and they make the P/E look lower than the business alone would.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about ACAD

How big is Acadia Pharmaceuticals?

Acadia Pharmaceuticals’ market cap is $3.04B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.20B: what customers paid the company over the last year, before any costs.

What is ACAD’s P/E ratio?

ACAD’s P/E ratio is 8.4×. Investors pay about 8.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with ACAD?

The business generates almost all of its revenue from only two approved prescription medicines. That is one risk on Acadia Pharmaceuticals’ card. Its first risk flag is Profit with Caveats, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Acadia Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ACAD’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card